<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03262454</url>
  </required_header>
  <id_info>
    <org_study_id>NCC2017-0229</org_study_id>
    <secondary_id>ML39728</secondary_id>
    <nct_id>NCT03262454</nct_id>
  </id_info>
  <brief_title>Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC</brief_title>
  <acronym>Atezolizumab</acronym>
  <official_title>Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for Recurrent or Refractory Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Korea co.,Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesized that local radiation therapy can enhance the effect of
      anti-PD-L1 monoclonal antibody through priming T-cell effector function against cancer cells.
      Described as above, The investigators concluded that modest dose of radiation to local site
      prior to immunotherapy is the best to enhance T-cell-mediated immunity. Accordingly, The
      investigators will investigate the combining effect of hypofractionated-sublethal dose of
      radiation therapy followed by anti-PD-L1 monoclonal antibody, atezolizumab, for SCLC patients
      who are recurrent or refractory for initial platinum-based chemotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Small cell lung cancer (SCLC), accounting for 10% of all lung cancers (Torre et al., 2015),
      shows poor outcomes with 7-10 months of median survival in advanced cases (Jett et al.,
      2013). Despite novel treatment strategies including targeted therapy and immunotherapy for
      non-small cell lung cancer (NSCLC) have been introduced, the treatment options for SCLC still
      remain limited. Many clinical trials, which tested the efficacy of molecular targeted agents
      for SCLC, failed to show clinical benefit compared with conventional platinum-based
      chemotherapy (Koinis et al., 2016). Nevertheless, recent studies demonstrated that
      immunotherapy using anti-CTLA-4 or anti-PD1 monoclonal antibody can be novel therapeutic
      strategies for SCLC (Ott et al., 2015; Reck et al., 2013; SJ et al., 2015).

      In recent years, many studies have shown that radiation therapy can be a useful treatment as
      a combining treatment with immunotherapy. The abscopal effect refers to the ability of
      radiation delivered radiation delivered to a local site to treat the other diseases outside
      radiation field (Tang et al., 2014). A recent study described that abscopal effect was
      observed in a malignant melanoma patient treated with CTLA4 antagonist and radiotherapy
      (Postow et al., 2012). Moreover, an animal study presented that blockade of PD-L1 and
      ionizing radiation showed synergism (Deng et al., 2014). Based on these emerging evidences,
      the investigators hypothesized that local radiation therapy can enhance the effect of
      anti-PD-L1 monoclonal antibody through increasing T-cell effector function against tumors.
      Atezolizumab, which is a humanized anti-PD-L1 monoclonal antibody, act as an inhibitor the
      interaction between PD-L1 and PD-1, and eventually restore suppressed T-cell immunity leading
      elimination of cancer cells. In this study, the investigators will investigate the combining
      effect of hypofractionated-sublethal dose of radiation therapy followed by anti-PD-L1
      monoclonal antibody, atezolizumab, for SCLC patients who are recurrent or refractory for
      initial platinum-based chemotherapy.

      Based on these emerging evidences, the investigators hypothesized that local radiation
      therapy can enhance the effect of anti-PD-L1 monoclonal antibody through priming T-cell
      effector function against cancer cells. Described as above, the investigators concluded that
      modest dose of radiation to local site prior to immunotherapy is the best to enhance
      T-cell-mediated immunity.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>through study completion, and average of 1 years</time_frame>
    <description>Objective Response rate using RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>From date of enroll until the date of first documented progression or date of death from any cause, whichever came first, assessed up to at least 12 months</time_frame>
    <description>Progression Free Survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Small Cell Lung Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>Interventions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atezolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Patients undergo hypofractionated radiation therapy with 24 Gy over 4 fractions in days 1-4 of 1st cycle of atezolimumab and receive Atezolizumab 1200 mg fixed dose via intravenous on day 1 of each 3-week cycle until disease progression or unacceptable toxicity occurs.</description>
    <arm_group_label>Interventions</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patient aged 18 years or older

          2. Histologically confirmed SCLC and available tumor tissues for PD-L1 staining

          3. Progression during or after platinum-based chemotherapy.

          4. At least one target tumor lesion that has not been irradiated within the past three
             months and that can accurately be measured in at least one dimension with longest
             diameter

          5. Life expectancy of at least three months

          6. Performance status of 0, 1, 2 on the ECOG criteria

          7. Adequate hematologic and end-organ function, Patients may be transfused or receive
             erythropoietic treatment to meet this criterion.

          8. Patient has given written informed consent which must be consistent with the
             International Conference on Harmonization - Good Clinical Practice (ICH-GCP) and local
             legislation

        Exclusion Criteria:

          1. Previous therapy with anti-PD-1 or -PD-L1 inhibitors

          2. Persistence of clinically relevant therapy related toxicities from previous
             chemotherapy and/or radiotherapy

          3. Chemotherapy, treatment with tyrosine kinase inhibitors, or radiotherapy (except for
             brain and extremities) within the past 3 weeks prior to treatment with the trial drug
             i.e., the minimum time elapsed since the last anticancer therapy and the first
             radiotherapy must be 3 weeks

          4. Treatment with other investigational drugs or treatment in another clinical trial
             within the past three weeks before start of therapy or concomitantly with this trial

          5. Concomitant yellow fever vaccination

          6. Active or untreated CNS metastases as determined by CT or MRI evaluation during
             screening and prior radiographic assessments

          7. Spinal cord compression not definitively treated with surgery and/or radiation or
             previously diagnosed and treated spinal cord compression without evidence that disease
             has been clinically stable for 2 weeks prior to randomization

          8. Leptomeningeal disease

          9. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent
             drainage procedures

         10. Uncontrolled tumor-related pain

         11. Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of
             bisphosphonate therapy or denosumab

         12. Significant cardiovascular diseases (i.e., hypertension not controlled by medical
             therapy, unstable angina, history of myocardial infarction within the past 12 months,
             congestive heart failure &gt; NYHA II, serious cardiac arrhythmia, pericardial effusion)

         13. Proteinuria CTCAE grade 2 or greater

         14. Significant weight loss (&gt; 10 %) within the past 6 weeks prior to treatment in the
             present trial

         15. Current peripheral neuropathy â‰¥ CTCAE(version4.0) Grade 2 except due to trauma

         16. Major injuries and/or surgery with incomplete wound healing within the past ten days
             prior to enrollment

         17. Serious infections requiring systemic antibiotic (e.g. antiviral, antimicrobial,
             antifungal) therapy

         18. Active hepatitis C and/or B infection

         19. Known human immunodeficiency virus (HIV) seropositivity

         20. Serious illness or concomitant non-oncological disease such as
             neurologic-,psychiatric-, infectious disease or active ulcers (gastro-intestinal
             tract, skin) or laboratory abnormality that may increase the risk associated with
             study participation or study drug administration and in the judgment of the
             investigator would make the patient inappropriate for entry into the study

         21. Patients who are sexually active and unwilling to use a medically acceptable method of
             contraception (e.g. such as implants, injectables, combined oral contraceptives, some
             intrauterine devices or vasectomized partner for participating females, condoms for
             participating males) during the trial and for at least 5 months after end of active
             therapy

         22. Pregnancy or breast feeding

         23. Psychological, familial, sociological or geographical factors potentially hampering
             compliance with the study protocol and follow-up schedule

         24. Patients unable to comply with the protocol

         25. Active alcohol or drug abuse

         26. Other malignancy within the past three years other than basal cell skin cancer or
             carcinoma in situ of the cervix
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji-Youn Han, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ji-Youn Han, Ph.D.</last_name>
    <phone>+82-31-920-1154</phone>
    <email>jymama@ncc.re.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sung Jin Yoon</last_name>
    <phone>+82-31-920-0399</phone>
    <email>sjyoon@ncc.re.kr</email>
  </overall_contact_backup>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2017</study_first_submitted>
  <study_first_submitted_qc>August 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2017</study_first_posted>
  <last_update_submitted>November 1, 2017</last_update_submitted>
  <last_update_submitted_qc>November 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Ji-youn Han</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

